Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Gerresheimer    GXI   DE000A0LD6E6

GERRESHEIMER (GXI)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Gerresheimer : acquires Sensile Medical / irrespective of that, increased growth and improved profitability expected mid-term due to two new major orders with temporarily higher capex / organic revenue guidance 2018 narrowed to upper end of range

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/11/2018 | 02:20pm EDT

DGAP-Ad-hoc: Gerresheimer AG / Key word(s): Mergers & Acquisitions
Gerresheimer acquires Sensile Medical / irrespective of that, increased growth and improved profitability expected mid-term due to two new major orders with temporarily higher capex / organic revenue guidance 2018 narrowed to upper end of range

11-Jul-2018 / 20:17 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Gerresheimer acquires Sensile Medical / irrespective of that, increased growth and improved profitability expected mid-term due to two new major orders with temporarily higher capex / organic revenue guidance 2018 narrowed to upper end of range

Duesseldorf, July 11, 2018 - With the acquisition of Sensile Medical AG, Switzerland ("Sensile Medical") under a share purchase agreement signed today, Gerresheimer is extending its business model in the direction of an Original Equipment Manufacturer (OEM) for drug delivery platforms with digital and electronic capabilities for pharmaceutical and biopharmaceutical customers. Sensile Medical develops innovative drug delivery products and platforms, including digital connected capabilities. It is already working highly successfully with customers on the development of devices for diabetics and patients with heart complaints. Depending on the attainment of contractually specified milestones, the purchase price will be a maximum of EUR 350m. The initial payment is EUR 175m.

Independently of this, Gerresheimer has secured two new major contracts: one for the manufacture of inhalers and another for prefillable syringes for a major heparin producer. At the same time, Gerresheimer has lost a significantly smaller order in the inhaler business resulting in a restructuring that will affect the plant in Küssnacht, Switzerland, which is to be closed by the end of 2019.

As a result and excluding Sensile Medical, there are changes in the planning of capital expenditures, profitability and revenues: For the years 2019 and 2020, capital expenditures are expected to be higher by two to a maximum of four percentage points of revenues at constant exchange rates, among other things for the capacity expansion at the plant in Horsovsky Tyn, Czech Republic; further automation; and a new plant in Eastern Europe. At the same time, Gerresheimer anticipates that this will lead in 2019 and 2020 to an approximately one-percentage-point reduction in the adjusted EBITDA margin (relative to the financial year 2017) as a consequence of low-margin revenues in the engineering and tooling business for the new major orders and of increased expenditures for relocation, employee training and production start-up/ramp-up.

In the years 2021 and 2022, Gerresheimer expects-again, excluding Sensile Medical-that both revenues and the adjusted EBITDA margin will increase by two percentage points beyond the usual rate of growth while capital expenditures will return to around 8%.
For the current year, following up on the guidance given on February 22, 2018, and excluding Sensile Medical, Gerresheimer anticipates a strong second half and has narrowed its forecast for revenues at constant exchange rates to the upper end of the guidance range, at EUR 1.38bn to EUR 1.4bn.


Contact Press                                                                  Contact Investor Relations
Jens Kürten                                                                     Severine Camp
Group Senior Director Communication & Marketing       Corporate Senior Director Investor Relations
Phone +49 211 6181-250                                                Phone +49 211 6181-314
Fax +49 211 6181-241                                                    Fax +49 211 6181-121
E-Mail j.kuerten@gerresheimer.com                               E-Mail s.camp@gerresheimer.com




Contact:
Severine Camp
Corporate Senior Director Investor Relations
Phone +49 211 6181-314
Fax +49 211 6181-121
E-Mail s.camp@gerresheimer.com

11-Jul-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Gerresheimer AG
Klaus-Bungert-Str. 4
40468 Düsseldorf
Germany
Phone: +49-(0)211/61 81-00
Fax: +49-(0)211/61 81-295
E-mail: s.camp@gerresheimer.com
Internet: http://www.gerresheimer.com
ISIN: DE000A0LD6E6, XS0626028566
WKN: A0LD6E, A1H3VP
Indices: MDAX (Aktie)
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of Announcement DGAP News Service

703763  11-Jul-2018 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=703763&application_name=news&site_id=zonebourse

© EQS 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GERRESHEIMER
09/21GERRESHEIMER : A great start to professional life
PU
09/19GERRESHEIMER AT CPHI WORLDWIDE : Gerresheimer to expand its services to include ..
PU
09/17GERRESHEIMER AT LUXEPACK 2018 : Gerresheimer’s new Decoration Center
PU
09/14GERRESHEIMER : Series production of Gx RTF ClearJect plastic syringes started
PU
09/12GERRESHEIMER AG : Release according to Article 40, Section 1 of the WpHG [the Ge..
EQ
09/12GERRESHEIMER AG : Release according to Article 40, Section 1 of the WpHG [the Ge..
EQ
09/12GERRESHEIMER : and Sensile Medical to attend CPhI Worldwide together for the fir..
PU
09/10GX® INNOSAFE : Greater protection against needle stick injuries
PU
09/10GERRESHEIMER : Dietmar Siemssen appointed new CEO of Gerresheimer AG
AQ
09/06GERRESHEIMER AG : Dietmar Siemssen appointed new CEO of Gerresheimer AG
EQ
More news
News from SeekingAlpha
04/13Gerresheimer AG ADR 2018 Q1 - Results - Earnings Call Slides 
02/23Gerresheimer AG ADR 2017 Q4 - Results - Earnings Call Slides 
2017Gerresheimer AG ADR 2017 Q3 - Results - Earnings Call Slides 
2015Corning buying German pharma glass tubing business for $219m 
Financials (€)
Sales 2018 1 370 M
EBIT 2018 162 M
Net income 2018 118 M
Debt 2018 828 M
Yield 2018 1,72%
P/E ratio 2018 18,30
P/E ratio 2019 24,77
EV / Sales 2018 2,24x
EV / Sales 2019 2,14x
Capitalization 2 240 M
Chart GERRESHEIMER
Duration : Period :
Gerresheimer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GERRESHEIMER
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 75,7 €
Spread / Average Target 6,1%
EPS Revisions
Managers
NameTitle
Axel Herberg Chairman-Supervisory Board
Rainer Beaujean Chief Financial Officer
Theodor Stuth Independent Member-Supervisory Board
Udo J. Vetter Independent Member-Supervisory Board
Francesco Grioli Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
GERRESHEIMER2.72%2 635
MEDTRONIC PLC21.18%133 512
BAXTER INTERNATIONAL19.83%41 539
ALIGN TECHNOLOGY76.87%31 241
ZIMMER BIOMET HOLDINGS8.15%26 705
TERUMO CORP22.12%22 497